Lakefront Biotherapeutics NV balance sheet

At the end of fiscal 2025, Lakefront Biotherapeutics NV had total assets of $4.00bn, total liabilities of $200m and shareholders' equity of $3.80bn. It held $103m in cash against $0 of debt: net cash of $103m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Lakefront Biotherapeutics NV: balance sheet, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash and equivalents	370	1,027	1,384	1,479	2,090	2,611	2,528	544	185	66	103
Receivables	4	10	34	21	61	182	126	43	31	49	24
Inventory	0	0	0	0	0	0	23	57	82	53	26
Total current assets	407	1,063	1,440	1,522	6,586	6,567	5,503	4,533	4,272	3,457	3,614
Goodwill	—	—	—	—	—	—	—	75	77	72	—
Total assets	481	1,143	1,546	1,649	6,813	6,993	5,878	5,065	4,820	4,281	3,998
Total current liabilities	79	110	206	252	642	777	641	559	474	347	179
Total debt	0	0	0	0	0	0	0	0	0	0	0
Total liabilities	84	343	330	258	3,585	3,727	2,886	2,362	1,728	1,282	200
Shareholders' equity	396	801	1,217	1,391	3,229	3,266	2,992	2,702	3,092	2,999	3,798
Net debt (negative = net cash)	−370	−1,027	−1,384	−1,479	−2,090	−2,611	−2,528	−544	−185	−66	−103

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: LKFT vs MDGL LKFT vs PTCT ACAD vs LKFT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Lakefront Biotherapeutics NV's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lakefront Biotherapeutics NV.